David M. Stoll, M.D.
Specialist
9735 Wilshire Blvd, Suite 418
Beverly Hills, CA 90212
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Vanderbilt University School of Medicine (1980)
- Years since graduation
- 46
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 388
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1980Medical school: Vanderbilt University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Specialist primary
CA license G045943
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 388
- Services billed
- 1,381
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 564 | 273 |
| Destruction of precancer skin growth, 15 or more growths | 285 | 150 |
| New patient office or other outpatient visit, 30-44 minutes | 90 | 90 |
| Destruction of precancer skin growth, 1 growth | 71 | 67 |
| Destruction of skin growth, 1-14 growths | 58 | 40 |
| Pathology examination of tissue using a microscope, intermediate complexity | 56 | 46 |
| Complicated or multiple drainage of skin abscess | 35 | 28 |
| Removal of cancer skin growth of body, arms, or legs, 0.5 cm or less | 19 | 16 |
| Removal of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 0.6-1.0 cm | 17 | 14 |
| Removal of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 0.5 cm or less | 16 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Triamcinolone Acetonide Other prescribers in Beverly Hills, CA | 78 |
| Fluocinonide Other prescribers in Beverly Hills, CA | 57 |
| Mupirocin Other prescribers in Beverly Hills, CA | 41 |
| Ciclopirox (ciclopirox olamine) | 37 |
| Betamethasone Dipropionate Other prescribers in Beverly Hills, CA | 27 |
| Alclometasone Dipropionate | 26 |
| Minoxidil Other prescribers in Beverly Hills, CA | 25 |
| Clobetasol Propionate Other prescribers in Beverly Hills, CA | 23 |
| Tretinoin | 21 |
| Ciclopirox Other prescribers in Beverly Hills, CA | 17 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 13 companies reported 44 payments worth $950 in total to this clinician.
| Amgen Inc. | $205 |
|---|---|
| Pfizer Inc. | $182 |
| Zimmer Biomet Holdings, Inc. | $126 |
| Sun Pharmaceutical Industries Inc. | $82.82 |
| Janssen Biotech, Inc. | $70.49 |
| Incyte Corporation | $67.98 |
| Leo Pharma Inc. | $57.09 |
| UCB, Inc. | $35.71 |
| Food and Beverage | $950 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 4 companies. The companies reported $523,888 in research payments for these studies, mostly to the institutions running them.
- TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis
Takeda Pharmaceuticals U.S.A., Inc. - A study about how well TAK-279 works and its safety in participants with moderate-to-severe plaque psoriasis during 60 weeks of treatment with a withdrawal and retreatment period
Takeda Pharmaceuticals U.S.A., Inc. - TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis
Takeda Pharmaceuticals U.S.A., Inc. - Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE)
Janssen Research & Development, LLC - A Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B)
UCB SA · Completed · NCT05277571 - A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis
Eli Lilly and Company · Completed · NCT06602219
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.